FDA delays review of two drugs under the commissioner's voucher programme amid safety and efficacy concerns; Eli Lilly (LLY) and Sanofi (SAN FP) targeted

The FDA's delay of the review for two drugs associated with Eli Lilly and Sanofi signals significant safety and efficacy concerns, potentially impacting their market strategies and share prices.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

JPMorgan (JPM) December net charge-offs 1.59% (prev. 1.76%), delinquencies 0.84% (prev. 0.86%)

Spotify (SPOT) is increasing prices for Premium subscribers in various regions. In the US, to USD 12.99/month (prev. 11.99/month)

FDA delays review of two drugs under the commissioner's voucher programme amid safety and efficacy concerns; Eli Lilly (LLY) and Sanofi (SAN FP) targeted

BlackRock Inc. (BLK) Q4 2025 (USD): adj. EPS 13.16 (exp. 12.27), Revenue 7.01bln (exp. 6.76bln)

Chinese Commerce Minister announces plan to expand and diversify markets for trade, via Xinhua

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This delay may also suggest heightened scrutiny from regulators, which could affect investor sentiment in the pharmaceutical sector, particularly for these companies. Watch for broader implications in equity performance and any potential shifts in regulatory approaches within the industry.

Related headlines

The whole workspace, free to try.

Try it free